AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
AbbVie (NYSE: ABBV) and Neomorph have announced a collaboration and option-to-license agreement to develop molecular glue degraders for oncology and immunology targets. The partnership combines AbbVie's expertise in drug development with Neomorph's molecular glue discovery platform.
Molecular glue degraders represent a novel class of small molecules designed to selectively target and trigger degradation of proteins involved in cancer growth and immune system dysregulation, including previously 'undruggable' proteins.
Under the agreement terms, Neomorph will receive an upfront payment and is eligible for up to $1.64 billion in option fees and milestones, plus tiered royalties on net sales.
AbbVie (NYSE: ABBV) e Neomorph hanno annunciato una collaborazione e un accordo di opzione per la licenza per sviluppare degradatori di colla molecolare per obiettivi in oncologia e immunologia. Questa partnership combina l'esperienza di AbbVie nello sviluppo di farmaci con la piattaforma di scoperta di colla molecolare di Neomorph.
I degradatori di colla molecolare rappresentano una nuova classe di piccole molecole progettate per colpire selettivamente e attivare la degradazione di proteine coinvolte nella crescita cancerosa e nella disfunzione del sistema immunitario, comprese le proteine precedentemente considerate 'non trattabili'.
Secondo i termini dell'accordo, Neomorph riceverà un pagamento iniziale ed è idonea a ricevere fino a 1,64 miliardi di dollari in diritti d'opzione e traguardi, oltre a royalties su vendite nette a scalare.
AbbVie (NYSE: ABBV) y Neomorph han anunciado una colaboración y un acuerdo de opción de licencia para desarrollar degradadores de pegamento molecular para objetivos de oncología e inmunología. Esta asociación combina la experiencia de AbbVie en el desarrollo de fármacos con la plataforma de descubrimiento de pegamento molecular de Neomorph.
Los degradadores de pegamento molecular representan una nueva clase de pequeñas moléculas diseñadas para dirigirse selectivamente y provocar la degradación de proteínas involucradas en el crecimiento del cáncer y en la disfunción del sistema inmunológico, incluidas las proteínas que anteriormente eran consideradas 'indruggables'.
Según los términos del acuerdo, Neomorph recibirá un pago inicial y es elegible para hasta 1.64 mil millones de dólares en tarifas de opción y hitos, además de regalías escalonadas sobre ventas netas.
AbbVie (NYSE: ABBV)와 Neomorph는 종양학 및 면역학 표적을 위한 분자 접착제 분해제를 개발하기 위한 협력 및 라이센스 옵션 계약을 발표했습니다. 이 파트너십은 AbbVie의 약물 개발 전문성과 Neomorph의 분자 접착제 발견 플랫폼을 결합합니다.
분자 접착제 분해제는 암 성장 및 면역 시스템 비정상에 관여하는 단백질을 선택적으로 표적으로 삼고 분해를 유도하도록 설계된 새로운 클래스의 소분자입니다. 여기에는 이전에 '약물화가 불가능한' 단백질이 포함됩니다.
계약 조건에 따라 Neomorph는 초기 지급금을 받고 최대 16억 4천만 달러의 옵션 수수료 및 이정표를 받을 수 있으며, 순 판매에 대한 단계별 로열티를 추가로 받을 수 있습니다.
AbbVie (NYSE: ABBV) et Neomorph ont annoncé une collaboration et un accord d'option de licence pour développer des déchippers de colle moléculaire pour des cibles oncologiques et immunologiques. Ce partenariat combine l'expertise d'AbbVie dans le développement de médicaments avec la plateforme de découverte de colle moléculaire de Neomorph.
Les déchippers de colle moléculaire représentent une nouvelle classe de petites molécules conçues pour cibler sélectivement et déclencher la dégradation de protéines impliquées dans la croissance du cancer et la dysrégulation du système immunitaire, y compris des protéines considérées auparavant comme 'indruggables'.
Selon les termes de l'accord, Neomorph recevra un paiement initial et pourra recevoir jusqu'à 1,64 milliard de dollars en frais d'option et en jalons, ainsi que des redevances échelonnées sur les ventes nettes.
AbbVie (NYSE: ABBV) und Neomorph haben eine Zusammenarbeit und einen Lizenzoptionsvertrag zur Entwicklung von molekularen Kleberabbauern für onkologische und immunologische Zielstrukturen angekündigt. Diese Partnerschaft vereint AbbVies Expertise in der Arzneimittelentwicklung mit Neomorphs Discovery-Plattform für molekulare Kleber.
Molekulare Kleberabbauer stellen eine neuartige Klasse von kleinen Molekülen dar, die darauf ausgelegt sind, selektiv zu wirken und den Abbau von Proteinen zu aktivieren, die am Krebswachstum und an der Dysregulation des Immunsystems beteiligt sind, einschließlich zuvor 'nicht behandelbarer' Proteine.
Gemäß den Vertragsbedingungen erhält Neomorph eine Vorauszahlung und ist berechtigt, bis zu 1,64 Milliarden Dollar an Optionsgebühren und Meilensteinen zu erhalten, plus gestaffelte Tantiemen auf Nettoumsätze.
- Agreement includes potential payments of up to $1.64 billion plus royalties
- Technology targets previously 'undruggable' proteins
- Expands AbbVie's oncology and immunology pipeline
- None.
Insights
This collaboration marks a strategic expansion of AbbVie's drug discovery capabilities, positioning the company at the forefront of molecular glue degrader technology - an emerging field that could revolutionize drug development. The deal structure, featuring milestone payments up to
The molecular glue degrader platform's ability to target previously 'undruggable' proteins is particularly significant for three reasons:
- It could potentially unlock new treatment pathways for resistant cancers and immune disorders, addressing substantial unmet medical needs
- It complements AbbVie's existing small molecule and biologics capabilities, potentially creating synergies with current development programs
- It provides a competitive advantage in the rapidly evolving protein degradation space, where companies like Arvinas and C4 Therapeutics are also making significant strides
From a financial perspective, while the
The collaboration could significantly impact AbbVie's long-term growth trajectory, particularly as the company seeks to diversify beyond Humira. Success in this venture could lead to multiple new drug candidates across oncology and immunology, potentially generating substantial revenue streams in the 2030s when many of today's blockbusters will face patent expiration.
- Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform
- Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to
$1.64B
Molecular glue degraders are a novel class of small molecules that are designed to selectively target and trigger degradation of proteins that drive cancer growth or immune system dysregulation, offering a more precise approach to treatment. Molecular glue degraders have the potential to target proteins that have historically been defined as "undruggable".
"Protein degraders represent a groundbreaking advancement in the field of drug discovery and at AbbVie we are committed to advancing this technology forward," said Steven Elmore, vice president, small molecule therapeutics and platform technologies at AbbVie. "We are excited to collaborate with Neomorph to develop novel molecular glue degraders which could pave the way for new, effective therapies in the treatment of immune disorders and cancer."
"At Neomorph, we have spent years building a unique molecular glue platform with broad coverage of the proteome," said Phil Chamberlain, DPhil, Co-Founder, President, and Chief Executive Officer of Neomorph. "We are thrilled to partner with AbbVie, a global leader in delivering transformative medicines in oncology and immunology, as we aim to tackle some of the most challenging and valuable targets known."
Under terms of the agreement, Neomorph will receive an upfront payment from AbbVie, and is eligible to receive up to
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
About Neomorph
Neomorph is a biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against 'undruggable' targets. Neomorph was founded in 2020 and is venture-backed by Deerfield Management Company.
Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who have a track record of groundbreaking discoveries in the field. The team at Neomorph is committed to leadership in advancing the science and technology of molecular glue drug discovery, while prosecuting a pipeline of projects through clinical development.
Neomorph is headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology-302357741.html
SOURCE AbbVie
FAQ
What is the value of AbbVie's (ABBV) collaboration deal with Neomorph?
What technology is AbbVie (ABBV) acquiring through the Neomorph partnership?
How will the Neomorph collaboration benefit AbbVie's (ABBV) drug development?
What therapeutic areas will AbbVie (ABBV) target with Neomorph's technology?
